DARKPOOL0.1.0
AFT-MKT Sign in
COAG
Hemab Therapeutics Holdings, Inc.
NMS Equity
39.33
+0.56 (+1.44%)
52w low 23.00 55.42 high
50.4% of range
Open
38.77
High
40.92
Low
36.07
Prev Close
38.77
Volume
655.78K
Avg Vol 3M
476.29K
Market Cap
1.84B
Currency
USD

6 Month Trend

full chart ›
— C-- Chg-- Gap-- Vol-- ×avg-- σ-- SMA20-- SMA50-- SMA200-- RSI-- SPY-- DD-- Bench-- Sig-- Hist-- hover · click to pin · ← → step · drag to zoom · shift-drag to measure
30.0040.0050.00May 26Jun 26Jul 26Aug 26Oct 26Nov 26
—Context
  • Move across the chart.

Company

SectorHealthcare
IndustryBiotechnology
CountryUnited States
Employees59
Website ↗

Performance

change over each horizon
1D +1.44%
5D -12.77%
1M +29.42%
3M -26.46%
6M +37.71%
YTD --
1Y --
2Y --
3Y --
5Y --
MAX +38.00%

Technical Rating

265 daily bars
Hold
2 bullish 3 bearish 1 neutral
SignalReading
+ Price vs 50-day average 39.33 vs 35.59
− Price vs 200-day average 39.33 vs 40.42
− 50-day vs 200-day 35.59 vs 40.42
− MACD histogram -0.529
+ 3-month rate of change +10.1%
· RSI (14) 48.1 (neutral)

A mechanical summary of past prices only — six indicators, one vote each. It uses no fundamentals, no news and no knowledge of your circumstances, and the signals disagree by design. Not investment advice.

ML Prediction

265 daily bars
HOLD
SignalReading
Predicted next close 37.74
Predicted change -4.04%
Trend FLAT
Support / Resistance 35.33 / 47.35
Track record none scored yet
  • model: -4.0%

A mechanical fit to past prices, nothing more — no fundamentals, no news, no view of your circumstances. Historically close to a coin flip on direction (see the backtest). Not investment advice.

Valuation

P/E Trailing--
P/E Forward-15.03x
Price / Book-0.01x
Price / Sales--
EV / EBITDA-17.76x
EPS Trailing-4.33
Dividend Yield0.00%
Beta--

Profitability

Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity--
Return on Assets--
Revenue Growth--
Debt / Equity0.00x
Current Ratio35.85x

Business

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Keys & commands

/focus the command box
AAPL Enteropen a ticker
apple Entersearch by company name (suggestions drop down as you type)
AAPL GPopen a ticker on a screen: DES, GP, FA
W PORT HZNwatchlist, portfolio, horizon
1–5DES, GP, W, FA, PORT for the current symbol
↑ ↓ Escmove through suggestions, close
?this reference

On a chart: hover for the readout, click to pin, drag to zoom, shift-drag to measure.